Skip to main content
IPSC logo

IPSC · Century Therapeutics, Inc.

Track IPSC — free
$1.29 -0.10 (-6.88%)
Market Cap
$250.60M
Shares
181.60M
Volume · Nov 19 109.88K Avg daily vol (3M) 738.85K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.38 Open$1.36 Day$1.32–1.46 52W close$0.49–2.94 Avg vol 30d946K Short int32.0M · 17.6% of shares · 31.0d Short vol56% Last earningsMar 19, 2025 DataJun 2021–Nov 2026 Filing10-Q · Nov 12

Latest documents

2026
Nov 12
Current report 8-K
Cash runway reaches 1Q 2029

Century Therapeutics reported $174.1 million in cash, cash equivalents and investments as of September 30, 2026, supporting operations into 1Q 2029; net loss was $23.5 million for the quarter ended September 30, 2026.

Financial results
2 source passages
Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $174.1 million as of September 30, 2026 Net Loss: Net loss was $23.5 million for the quarter ended September 30, 2026, compared to a net loss of $34.4 million for the same period in 2025. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash runway extends into first quarter of 2029

Century Therapeutics targets CNTY-813 IND submission in the fourth quarter of 2026 and initial clinical data in the second half of 2027. Its $174.1 million in cash, cash equivalents and investments will fund operations into the first quarter of 2029.

Net loss $23.45M Diluted EPS -$0.11
Read from the MD&A section
2 source passages
We continue to advance CNTY-813 through IND-enabling studies and expect to submit an IND for CNTY-813 in the fourth quarter of 2026. We anticipate initial clinical data in the second half of 2027, subject to completion of remaining IND-enabling studies and regulatory clearance. Based on our current business plans, we believe our cash, cash equivalents and investments as of September 30, 2026 of $174.1 million will be sufficient for us to fund our operating expenses and capital expenditure requirements into the first quarter of 2029. Open the document at this passage
Oct 2
Current report 8-K
Regulation FD disclosure, Other events

Century Therapeutics reported CNTY-813 sustained glycemic control for over eleven months, showed consistent production across five clinical-scale batches, and remained functional after 96 hours of cold storage; IND submission is targeted for Q4 2026 and initial clinical data for 2H 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$109.16M
Trailing 12 months
Net income (TTM)
−$98.83M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-15.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+138.8%
Year over year · more shares
Price change (1Y)
+181.6%
Trailing year
Short interest
17.6%
Latest settlement · 31.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −14%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 36%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Weak
1-month return −14%
trailing
6-month return −44%
trailing
YTD return +39%
this year
Relative strength −40%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +19 funds added
Insider flow Distributing
Net -$10.2K over 90 days · 100% sells
Short interest Rising
17.64% of shares out · ▲ +9.9% MoM · 31.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
103 holders — near 3-yr high, broad support
Squeeze score 84
high risk · 0–100
Fundamentals
Strong
Revenue growth +1557%
Y/Y
EPS growth +91%
Y/Y
Free cash flow $-104.7M
Quant / Vol
risk profile
Very High
Volatility 103%
annualized · 1-yr
Max drawdown −56%
past year
ATR 12.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed May 11, 2023
GAAP operating expenses · full year GAAP $135M – $145M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
36% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +19 funds added
Insider flow Distributing
Net -$10.2K over 90 days · 100% sells
Short interest Rising
17.64% of shares out · ▲ +9.9% MoM · 31.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
103 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $1 · 36% Range high $3
vs 200-day avg -33% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IPSC
Century Therapeutics, Inc.
this stock
$250.60M +38.7% +1556.8% — 17.6%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
103
% held
89.8%
Net QoQ
+5.0M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
91
View
Short & Settlement
Short Interest Rising
Shares short
32.0M
Days to cover
31.0d
Change
+2.9M sh
View
Short Volume
Short vol %
56%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
66.4K
Value
$96.3K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
40.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$10.2K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$109.2M
Net income (FY)
$-9.6M
EPS diluted
$-0.14
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
23

Century Therapeutics targets CNTY-813 IND submission in the fourth quarter of 2026 and initial clinical data in the second half of 2027. Its $174.1 million in cash, cash equivalents and investments will fund operations into the first quarter of 2029.

View
Proposed Sales
Value
$404
Shares
266
Filed
Nov 3, 2026
View
Exempt Offerings
Offering
$160.0M
Filed
Mar 15, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Century Therapeutics Reports Thir…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
IPSC -20.7% -14.3% -43.7% -6.1% +38.7%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -16.8% -8.7% -40.2% -2.7% +31.6%
Key facts CIK 1850119 CUSIP 15673T100 13F (30d) 115 filings 99 filers Visit website Investor relations